• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中心阅片者评估克罗恩病患者内镜表现的可靠性。

Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease.

机构信息

Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada Department of Medicine, University of Western Ontario, London, Ontario, Canada.

Robarts Clinical Trials, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada Department of Epidemiology and Biostatistics, University of Western Ontario, London, Ontario, Canada.

出版信息

Gut. 2016 Jul;65(7):1119-25. doi: 10.1136/gutjnl-2014-308973. Epub 2015 May 2.

DOI:10.1136/gutjnl-2014-308973
PMID:25935574
Abstract

OBJECTIVE

The Crohn's Disease Endoscopic Index of Severity (CDEIS) and Simple Endoscopic Score for Crohn's Disease (SES-CD) are commonly used to assess Crohn's disease (CD) activity; however, neither instrument has been fully validated. We assessed intra-rater and inter-rater reliability of these indices.

DESIGN

Video recordings of colonoscopies obtained from 50 patients with CD who participated in an induction trial of a biological therapy were triplicated and reviewed in random order by four central readers. Data were used to assess intra-rater and inter-rater reliability for CDEIS, SES-CD and a global evaluation of lesion severity (GELS). Subsequently, readers participated in a consensus process that identified common sources of disagreement.

RESULTS

Intraclass correlation coefficients (ICCs) for intra-rater reliability for CDEIS, SES-CD and GELS (95% CIs) were 0.89 (0.86 to 0.93), 0.91 (0.89 to 0.95) and 0.81 (0.77 to 0.89), respectively, with standard error of measurement (SEM) of 2.10, 2.42 and 1.15. The corresponding ICCs for inter-rater reliability were 0.71 (0.63 to 0.76), 0.83 (0.75 to 0.88) and 0.62 (0.52 to 0.70), with SEM of 3.42, 3.07 and 1.63, respectively. Correlation between CDEIS and GELS was 0.75, between SES-CD and GELS was 0.74 and between CDEIS and SES-CD was 0.92. The most common sources of disagreement were interpretation of superficial ulceration, definition of disease site at the ileocolonic anastomosis, assessment of anorectal lesions and grading severity of stenosis.

CONCLUSIONS

Central reading of CDEIS and SES-CD had 'substantial' to 'almost perfect' intra-rater and inter-rater reliability; however, the responsiveness of these instruments is yet to be determined.

TRIAL REGISTRATION NUMBER

Clinicaltrials.gov NCT01466374.

摘要

目的

克罗恩病内镜严重程度指数(CDEIS)和简单克罗恩病内镜评分(SES-CD)常用于评估克罗恩病(CD)的活动度;然而,这两种方法都尚未得到充分验证。本研究旨在评估这两种方法的观察者内和观察者间可靠性。

设计

对参加生物治疗诱导试验的 50 例 CD 患者的结肠镜录像进行了三次复制,并由 4 位中心读者随机进行了回顾性评估。数据用于评估 CDEIS、SES-CD 和病变严重程度的整体评估(GELS)的观察者内和观察者间可靠性。随后,读者参与了一个共识过程,确定了常见的意见分歧来源。

结果

CDEIS、SES-CD 和 GELS 的观察者内可靠性的组内相关系数(ICC)(95%CI)分别为 0.89(0.86 至 0.93)、0.91(0.89 至 0.95)和 0.81(0.77 至 0.89),测量误差(SEM)分别为 2.10、2.42 和 1.15。观察者间可靠性的相应 ICC 分别为 0.71(0.63 至 0.76)、0.83(0.75 至 0.88)和 0.62(0.52 至 0.70),SEM 分别为 3.42、3.07 和 1.63。CDEIS 与 GELS 之间的相关性为 0.75,SES-CD 与 GELS 之间的相关性为 0.74,CDEIS 与 SES-CD 之间的相关性为 0.92。最常见的意见分歧来源是对表浅性溃疡的解释、回肠结肠吻合口处疾病部位的定义、肛直肠病变的评估和狭窄严重程度的分级。

结论

CDEIS 和 SES-CD 的中心读取具有“高度”至“几乎完美”的观察者内和观察者间可靠性;然而,这些工具的反应性尚待确定。

试验注册

Clinicaltrials.gov NCT01466374。

相似文献

1
Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease.中心阅片者评估克罗恩病患者内镜表现的可靠性。
Gut. 2016 Jul;65(7):1119-25. doi: 10.1136/gutjnl-2014-308973. Epub 2015 May 2.
2
Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease.标准化评分规范对克罗恩病内镜评估中评分者间信度的影响
J Crohns Colitis. 2016 Sep;10(9):1006-14. doi: 10.1093/ecco-jcc/jjw120. Epub 2016 Jul 6.
3
Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.克罗恩病疾病活动度的内镜指标反应性
Am J Gastroenterol. 2017 Oct;112(10):1584-1592. doi: 10.1038/ajg.2016.580. Epub 2017 Jan 10.
4
Endoscopic scoring indices for evaluation of disease activity in Crohn's disease.用于评估克罗恩病疾病活动度的内镜评分指标。
Cochrane Database Syst Rev. 2016 Aug 8;2016(8):CD010642. doi: 10.1002/14651858.CD010642.pub2.
5
Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.克罗恩病的回结肠镜评分的部位和中心读数的一致性:EXTEND 试验数据比较。
Gastrointest Endosc. 2016 Jan;83(1):188-97.e1-3. doi: 10.1016/j.gie.2015.06.018. Epub 2015 Jul 30.
6
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.基于 SONIC 数据的事后分析验证克罗恩病患者内镜活动评分的有效性。
Gastroenterology. 2013 Nov;145(5):978-986.e5. doi: 10.1053/j.gastro.2013.08.010. Epub 2013 Aug 14.
7
Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD.克罗恩病活动的内镜评估:CDEIS 与 SES-CD 的比较。
Inflamm Bowel Dis. 2010 Dec;16(12):2131-6. doi: 10.1002/ibd.21300.
8
Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis.内镜评估 pouchitis 中中心读者间评估的可靠性。
Gastrointest Endosc. 2018 Aug;88(2):360-369.e2. doi: 10.1016/j.gie.2018.04.2330. Epub 2018 Apr 13.
9
Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD).内镜评分系统中的观察者间一致性:来自意大利炎症性肠病研究组(IG-IBD)一项正在进行的研究的初步报告。
Dig Liver Dis. 2014 Nov;46(11):969-73. doi: 10.1016/j.dld.2014.07.010. Epub 2014 Aug 19.
10
Editorial: Endoscopic Scoring Systems in Crohn's Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment?社论:用于评估克罗恩病治疗反应性的内镜评分系统:我们是否已准备好迎接内镜评估的黄金时代?
Am J Gastroenterol. 2017 Oct;112(10):1593-1595. doi: 10.1038/ajg.2017.229.

引用本文的文献

1
Pathology assessment of inflammatory bowel disease - prospective study from two referral centers.炎症性肠病的病理学评估——来自两个转诊中心的前瞻性研究
Rom J Morphol Embryol. 2025 Jan-Mar;66(1):205-215. doi: 10.47162/RJME.66.1.19.
2
Artificial Intelligence-Enabled Clinical Trials in Inflammatory Bowel Disease: Automating and Enhancing Disease Assessment and Study Management.炎症性肠病中基于人工智能的临床试验:实现疾病评估与研究管理的自动化并加以强化。
Gastroenterology. 2025 Aug;169(3):432-443. doi: 10.1053/j.gastro.2025.02.039. Epub 2025 Mar 28.
3
Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review.
人工智能将彻底改变炎症性肠病临床试验:全面综述。
Therap Adv Gastroenterol. 2025 Feb 23;18:17562848251321915. doi: 10.1177/17562848251321915. eCollection 2025.
4
Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease.CT 肠造影术描述纤维狭窄性克罗恩病的可靠性。
Radiology. 2024 Aug;312(2):e233038. doi: 10.1148/radiol.233038.
5
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease.克罗恩病临床及内镜结果测量的可靠性与反应性
Inflamm Bowel Dis. 2025 Mar 3;31(3):706-715. doi: 10.1093/ibd/izae089.
6
Artificial Intelligence and IBD: Where are We Now and Where Will We Be in the Future?人工智能与 IBD:我们现在在哪里,未来将在哪里?
Curr Gastroenterol Rep. 2024 May;26(5):137-144. doi: 10.1007/s11894-024-00918-8. Epub 2024 Feb 27.
7
Review on Advances in Pediatric Endoscopy in the Management of Inflammatory Bowel Disease.小儿内镜在炎症性肠病管理中的进展综述
Curr Pediatr Rev. 2025;21(2):154-165. doi: 10.2174/0115733963268547231128101929.
8
Endoscopy in IBD: When and How?炎症性肠病中的内镜检查:时机与方式?
Diagnostics (Basel). 2023 Nov 10;13(22):3423. doi: 10.3390/diagnostics13223423.
9
Body composition parameters correlate with the endoscopic severity in Crohn's disease patients treated with infliximab.在接受英夫利昔单抗治疗的克罗恩病患者中,身体成分参数与内镜严重程度相关。
Front Nutr. 2023 Aug 21;10:1251448. doi: 10.3389/fnut.2023.1251448. eCollection 2023.
10
How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?在实际临床实践中,STRIDE-II治疗目标的可实现程度如何,以及这些目标能否预测长期治疗结果?
Frontline Gastroenterol. 2022 Dec 7;14(4):312-318. doi: 10.1136/flgastro-2022-102309. eCollection 2023.